Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

TFX vs ANGO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TFX
Teleflex Incorporated

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$5.83B
5Y Perf.-63.3%
ANGO
AngioDynamics, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$469M
5Y Perf.+9.7%

TFX vs ANGO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TFX logoTFX
ANGO logoANGO
IndustryMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$5.83B$469M
Revenue (TTM)$2.81B$307M
Net Income (TTM)$-1.01B$-28M
Gross Margin53.3%53.7%
Operating Margin5.6%-9.4%
Forward P/E19.6x
Total Debt$2.73B$0.00
Cash & Equiv.$393M$56M

TFX vs ANGOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TFX
ANGO
StockMay 20May 26Return
Teleflex Incorporat… (TFX)10036.7-63.3%
AngioDynamics, Inc. (ANGO)100109.7+9.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TFX vs ANGO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ANGO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Teleflex Incorporated is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
TFX
Teleflex Incorporated
The Income Pick

TFX is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.06, yield 1.0%
  • Lower volatility, beta 1.06, Low D/E 87.2%, current ratio 2.54x
  • Beta 1.06, yield 1.0%, current ratio 2.54x
Best for: income & stability and sleep-well-at-night
ANGO
AngioDynamics, Inc.
The Growth Play

ANGO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth -3.8%, EPS growth 81.9%, 3Y rev CAGR -2.6%
  • -9.2% 10Y total return vs TFX's -10.3%
  • -3.8% revenue growth vs TFX's -34.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthANGO logoANGO-3.8% revenue growth vs TFX's -34.6%
Quality / MarginsANGO logoANGO-9.0% margin vs TFX's -35.9%
Stability / SafetyTFX logoTFXBeta 1.06 vs ANGO's 1.32
DividendsTFX logoTFX1.0% yield; the other pay no meaningful dividend
Momentum (1Y)ANGO logoANGO+28.5% vs TFX's +9.0%
Efficiency (ROA)ANGO logoANGO-10.3% ROA vs TFX's -13.9%, ROIC -22.9% vs 3.4%

TFX vs ANGO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TFXTeleflex Incorporated
FY 2025
Vascular Access
46.1%$918M
Interventional
32.5%$648M
Surgical
21.0%$418M
Other
0.5%$9M
ANGOAngioDynamics, Inc.
FY 2024
Med Device
65.0%$198M
Med Tech
35.0%$106M

TFX vs ANGO — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLANGOLAGGINGTFX

Income & Cash Flow (Last 12 Months)

ANGO leads this category, winning 4 of 6 comparable metrics.

TFX is the larger business by revenue, generating $2.8B annually — 9.1x ANGO's $307M. ANGO is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to TFX's -35.9%. On growth, ANGO holds the edge at +9.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
RevenueTrailing 12 months$2.8B$307M
EBITDAEarnings before interest/tax$280M-$5M
Net IncomeAfter-tax profit-$1.0B-$28M
Free Cash FlowCash after capex$249M-$9M
Gross MarginGross profit ÷ Revenue+53.3%+53.7%
Operating MarginEBIT ÷ Revenue+5.6%-9.4%
Net MarginNet income ÷ Revenue-35.9%-9.0%
FCF MarginFCF ÷ Revenue+8.9%-3.0%
Rev. Growth (YoY)Latest quarter vs prior year-21.8%+9.0%
EPS Growth (YoY)Latest quarter vs prior year-108.7%+42.3%
ANGO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ANGO leads this category, winning 2 of 3 comparable metrics.
MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
Market CapShares × price$5.8B$469M
Enterprise ValueMkt cap + debt − cash$8.2B$413M
Trailing P/EPrice ÷ TTM EPS-6.50x-13.58x
Forward P/EPrice ÷ next-FY EPS est.19.59x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple18.82x
Price / SalesMarket cap ÷ Revenue2.93x1.60x
Price / BookPrice ÷ Book value/share1.88x2.52x
Price / FCFMarket cap ÷ FCF23.75x
ANGO leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ANGO leads this category, winning 4 of 7 comparable metrics.

ANGO delivers a -15.7% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-28 for TFX.

MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
ROE (TTM)Return on equity-28.3%-15.7%
ROA (TTM)Return on assets-13.9%-10.3%
ROICReturn on invested capital+3.4%-22.9%
ROCEReturn on capital employed+4.0%-18.6%
Piotroski ScoreFundamental quality 0–955
Debt / EquityFinancial leverage0.87x
Net DebtTotal debt minus cash$2.3B-$56M
Cash & Equiv.Liquid assets$393M$56M
Total DebtShort + long-term debt$2.7B$0
Interest CoverageEBIT ÷ Interest expense-2.02x-258.19x
ANGO leads this category, winning 4 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

ANGO leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in ANGO five years ago would be worth $4,674 today (with dividends reinvested), compared to $3,357 for TFX. Over the past 12 months, ANGO leads with a +28.5% total return vs TFX's +9.0%. The 3-year compound annual growth rate (CAGR) favors ANGO at 7.9% vs TFX's -19.4% — a key indicator of consistent wealth creation.

MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
YTD ReturnYear-to-date+7.9%-11.1%
1-Year ReturnPast 12 months+9.0%+28.5%
3-Year ReturnCumulative with dividends-47.6%+25.8%
5-Year ReturnCumulative with dividends-66.4%-53.3%
10-Year ReturnCumulative with dividends-10.3%-9.2%
CAGR (3Y)Annualised 3-year return-19.4%+7.9%
ANGO leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

TFX leads this category, winning 2 of 2 comparable metrics.

TFX is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than ANGO's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TFX currently trades 94.3% from its 52-week high vs ANGO's 80.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
Beta (5Y)Sensitivity to S&P 5001.03x1.32x
52-Week HighHighest price in past year$139.63$13.99
52-Week LowLowest price in past year$100.18$8.36
% of 52W HighCurrent price vs 52-week peak+94.3%+80.6%
RSI (14)Momentum oscillator 0–10048.554.0
Avg Volume (50D)Average daily shares traded884K395K
TFX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates TFX as "Buy" and ANGO as "Hold". Consensus price targets imply 46.4% upside for ANGO (target: $17) vs 0.4% for TFX (target: $132). TFX is the only dividend payer here at 1.02% yield — a key consideration for income-focused portfolios.

MetricTFX logoTFXTeleflex Incorpor…ANGO logoANGOAngioDynamics, In…
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$132.20$16.50
# AnalystsCovering analysts2911
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$1.35
Buyback YieldShare repurchases ÷ mkt cap+5.1%+0.4%
Insufficient data to determine a leader in this category.
Key Takeaway

ANGO leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). TFX leads in 1 (Risk & Volatility).

Best OverallAngioDynamics, Inc. (ANGO)Leads 4 of 6 categories
Loading custom metrics...

TFX vs ANGO: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is TFX or ANGO a better buy right now?

For growth investors, AngioDynamics, Inc.

(ANGO) is the stronger pick with -3. 8% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Analysts rate Teleflex Incorporated (TFX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TFX or ANGO?

Over the past 5 years, AngioDynamics, Inc.

(ANGO) delivered a total return of -53. 3%, compared to -66. 4% for Teleflex Incorporated (TFX). Over 10 years, the gap is even starker: ANGO returned -9. 2% versus TFX's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TFX or ANGO?

By beta (market sensitivity over 5 years), Teleflex Incorporated (TFX) is the lower-risk stock at 1.

03β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 28% more volatile than TFX relative to the S&P 500.

04

Which is growing faster — TFX or ANGO?

By revenue growth (latest reported year), AngioDynamics, Inc.

(ANGO) is pulling ahead at -3. 8% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, ANGO leads at -2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TFX or ANGO?

AngioDynamics, Inc.

(ANGO) is the more profitable company, earning -11. 6% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps -11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TFX leads at 12. 8% versus -13. 7% for ANGO. At the gross margin level — before operating expenses — TFX leads at 56. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is TFX or ANGO more undervalued right now?

Analyst consensus price targets imply the most upside for ANGO: 46.

4% to $16. 50.

07

Which pays a better dividend — TFX or ANGO?

In this comparison, TFX (1.

0% yield) pays a dividend. ANGO does not pay a meaningful dividend and should not be held primarily for income.

08

Is TFX or ANGO better for a retirement portfolio?

For long-horizon retirement investors, Teleflex Incorporated (TFX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

03), 1. 0% yield). Both have compounded well over 10 years (TFX: -9. 4%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between TFX and ANGO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TFX pays a dividend while ANGO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

TFX

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

ANGO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 32%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TFX and ANGO on the metrics below

Revenue Growth>
%
(TFX: -21.8% · ANGO: 9.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.